Evotec shares rise 2.36% premarket after reporting strong H1 2025 results and progress in collaborations with Bristol Myers Squibb.

Evotec SE rose 2.36% in premarket trading, driven by the company's H1 2025 results, which showed strong progress on strategy execution. The company reported a revenue mix aligned with its new strategy for sustainable profitable growth, with the Discovery & Preclinical Development segment renamed to better reflect its strategic focus. The Just – Evotec Biologics segment exceeded expectations due to a broadened customer base, and key progress was made in collaborations with Bristol Myers Squibb.